Abstract
This application claims aryl-substituted arylsulfonamidophenoxyacetic acid derivatives, and their use for the treatment of allergic and immune disease such as asthma and allergic rhinitis. The claimed compounds represent a novel class of prostaglandin D2 (PGD2) antagonists active at the CRTH2 receptor. The compounds bear some resemblance to older, arylsulfonamide TPreceptor antagonists.